Transmission and prevention
Herpes
is contracted through direct contact with an active lesion or body fluid
of an infected person. Herpes transmission occurs between discordant
partners; a person with a history of infection (HSV seropositive) can
pass the virus to an HSV seronegative person. While herpes virus type
2 has been demonstrated to remain viable on toilet seats for 2 to 4
hours after contact and on dry gauze for up to 72 hours, as of the submission
of those findings (1984) there were no documented cases of infection
via an inanimate object (e.g. a towel, toilet seat, drinking vessels).
To infect a new individual, HSV travels through tiny breaks in the skin
or mucous membranes in the mouth or genital areas. Even microscopic
abrasions on mucous membranes are sufficient to allow viral entry.
HSV
asymptomatic shedding occurs at some time in most individuals infected
with herpes. It can occur more than a week before or after a symptomatic
recurrence in 50% of cases. Infected people that show no visible symptoms
may still shed and transmit virus through their skin; asymptomatic shedding
may represent the most common form of HSV-2 transmission. Asymptomatic
shedding is more frequent within the first 12 months of acquiring HSV.
Concurrent infection with HIV increases the frequency and duration of
asymptomatic shedding. There are indications that some individuals may
have much lower patterns of shedding, but evidence supporting this is
not fully verified; no significant differences are seen in the frequency
of asymptomatic shedding when comparing persons with 1 to 12 annual
recurrences to those that have no recurrences.
Antibodies
that develop following an initial infection with a type of HSV prevents
reinfection with the same virus type—a person with a history of
orofacial infection caused by HSV-1 cannot contract herpes whitlow or
a genital infection caused by HSV-1. In a monogamous couple, a seronegative
female runs a greater than 30% per year risk of contracting an HSV infection
from a seropositive male partner. If an oral HSV-1 infection is contracted
first, seroconversion will have occurred after 6 weeks to provide protective
antibodies against a future genital HSV-1 infection.
For
genital herpes, condoms are highly effective in limiting transmission
of herpes simplex infection. The virus cannot pass through latex, but
a condom's effectiveness is somewhat limited on a public health scale
by their limited use in the community, and on an individual scale because
the condom may not completely cover blisters on the penis of an infected
male, or the base of the penis or testicles not covered by the condom
may come into contact with free virus in vaginal fluid of an infected
female. In such cases, abstinence from sexual activity or washing of
the genitals after sex is recommended. The use of condoms or dental
dams also limits the transmission of herpes from the genitals of one
partner to the mouth of the other (or vice versa) during oral sex. When
one partner has a herpes simplex infection and the other does not, the
use of antiviral medication, such as valaciclovir, in conjunction with
a condom, further decreases the chances of transmission to the uninfected
partner. Topical microbicides which contain chemicals that directly
inactivate the virus and block viral entry are currently being investigated.
Vaccines for HSV are currently undergoing trials. Once developed, they
may be used to help with prevention or minimize initial infections as
well as treatment for existing infections.
As
with almost all sexually transmitted infections, women are more susceptible
to acquiring genital HSV-2 than men.On an annual basis, without the
use of antivirals or condoms, the transmission risk of HSV-2 from infected
male to female is approximately 8-10%. This is believed to be due to
the increased exposure of mucosal tissue to potential infection sites.
Transmission risk from infected female to male is approximately 4-5%
annually. Suppressive antiviral therapy reduces these risks by 50%.
Antivirals also help prevent the development of symptomatic HSV in infection
scenarios—meaning the infected partner will be seropositive but
symptom free—by about 50%. Condom use also reduces the transmission
risk by 50%. Condom use is much more effective at preventing male to
female transmission than vice-versa. The effects of combining antiviral
and condom use is roughly additive, thus resulting in approximately
a 75% combined reduction in annual transmission risk.[citation needed]
These figures reflect experiences with subjects having frequently-recurring
genital herpes (>6 recurrences per year). Subjects with low recurrence
rates and those with no clinical manifestations were excluded from these
studies.[citation needed]
To
prevent neonatal infections, seronegative women are recommended to avoid
unprotected oral-genital contact with an HSV-1 seropositive partner
and conventional sex with a partner having a genital infection during
the last trimester of pregnancy. A seronegative mother that contracts
HSV at this time has up to a 57% chance of conveying the infection to
her baby during childbirth, since insufficient time will have occurred
for the generation and transfer of protective maternal antibodies before
the birth of the child, whereas a woman seropositive for both HSV-1
and HSV-2 has around a 1-3% chance of transmitting infection to her
infant. Women that are seropositive for only one type of HSV are only
half as likely to transmit HSV as infected seronegative mothers. Mothers
infected with HSV are advised to avoid procedures that would cause trauma
to the infant during birth (e.g., fetal scalp electrodes, forceps, and
vacuum extractors) and, should lesions be present, to elect caesarean
section to reduce exposure of the child to infected secretions in the
birth canal.The use of antiviral treatments, such as aciclovir, given
from the 36th week of pregnancy limits HSV recurrence and shedding during
childbirth, thereby reducing the need for caesarean section.
HSV-2
infected individuals are at higher risk for acquiring HIV when practicing
unprotected sex with HIV positive persons, particularly during an outbreak
with active lesions.